CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K.Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Seung Kim, Sei Hyun Baik
Diabetes Metab J. 2021;45(4):606-612.   Published online September 9, 2020
DOI: https://doi.org/10.4093/dmj.2020.0047

Excel Download

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
Diabetes & Metabolism Journal. 2021;45(4):606-612   Crossref logo
Link1 Link2 Link3

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes
Diabetes, Obesity and Metabolism. 2012;15(5):410-416   Crossref logo
Link1 Link2

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes ( TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
Diabetes, Obesity and Metabolism. 2021;24(4):609-619   Crossref logo
Link1 Link2 Link3

A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone
Diabetes, Obesity and Metabolism. 2018;20(6):1535-1541   Crossref logo
Link1 Link2

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
Journal of Diabetes Investigation. 2020;11(3):662-671   Crossref logo
Link1 Link2 Link3

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)
Diabetes, Obesity and Metabolism. 2018;20(5):1176-1185   Crossref logo
Link1 Link2 Link3 Link4

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study
Journal of Diabetes Investigation. 2017;9(1):108-118   Crossref logo
Link1 Link2

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
Diabetes mellitus. 2011;14(4):75-80   Crossref logo
Link1 Link2

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study
Diabetology International. 2018;10(1):37-50   Crossref logo
Link1 Link2 Link3

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension
Diabetes, Obesity and Metabolism. 2013;16(5):418-425   Crossref logo
Link1 Link2